S2409 PRISM: Biomarker-Driven ES-SCLC Therapy

Who Can Participate in the Study?

Age Group
Adults

Study Details

Full Title
Protocol S2409, PRISM: PRecIsion in SCLC via a Multicohort Study: Randomized Phase II studies evaluating maintenance Durvalumab with or without Biomarker-Directed Therapy for Extensive Stage Small Cell Lung Cancer (ES-SCLC) (NCT# 06769126)
Principal Investigator
Headshot of Laura Ruth Alder
Assistant Professor of Medicine
Protocol Number
IRB: PRO00119900
NCT: NCT06769126
Phase
Phase II
ClinicalTrials.gov
Enrollment Status
OPEN TO ACCRUAL